Answers are grounded in this paper and cite their sources.
Background Survival rates for non-small cell lung cancer (NSCLC) are low, due to the challenge in replicating it in preclinical models, limiting the discovery of effective treatments. Most preclinical models rely on two-dimensional (2D) cancer cell cultures, which retain several genomic and functional tumor features. However, these systems lack the spatial organization and microenvironmental gradients characteristic of three-dimensional (3D) tumor architecture, which influence cell behavior and gene regulation. 3D cell culture models, such as spheroids, can improve the therapeutic predictiveness of preclinical models. Yet, the transcriptomic and epigenomic changes underlying the transition from 2D to 3D culture that faithfully replicate NSCLC remain unknown. Methods We optimized a protocol enabling long-term (> 24 days) 3D spheroid culture of NSCLC cell lines. We investigated transcriptomic and epigenomic profiles over time using bulk RNA-seq, ChIP-seq and WGBS. Single-cell RNA-seq was performed to compare the changes in 2D and 3D cultures to NSCLC patient samples. We performed drug screens to compare the therapeutic vulnerabilities of 3D spheroids with 2D cultures and analyzed their plasticity upon returning to 2D culture, at the single-cell transcriptomic and pharmacological levels. Results NSCLC cells within spheroids revealed significant progressive epigenomic and transcriptomic remodeling over time. While DNA methylation remained stable, we observed dynamic changes in the methylation and acetylation of histones H3 and H4 that recapitulated those observed in NSCLC. Accordingly, single-cell transcriptomic profiles after 24 days of 3D culture were significantly more correlated with those of NSCLC patient tumors. Long-term spheroid culture increased the stringency of drug screening, inducing resistance to compounds that showed promise in many preclinical studies but failed in clinical trials (e.g., histone deacetylase (HDAC) inhibitors). We demonstrated novel pharmacological vulnerabilities and synergistic interactions (e.g., between protein arginine methyltransferase and HDAC inhibitors). Strikingly, reverting long-term 3D spheroids to 2D culture reversed transcriptomic, epigenetic, and pharmacological signatures within 7 days, demonstrating how cell culture conditions can impact preclinical outcomes. Conclusions Our findings highlight the value of long-term 3D culture, as compared to short-term spheroids and 2D culture to improve preclinical studies. This method could be adapted to other cancer cell lines to improve preclinical drug development and maximize clinical trial results.
No takes yet. Share an insight, caveat, or question.
Darracq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: